Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 134

1.

Non-contraceptive oestrogen-containing preparations for controlling symptoms of premenstrual syndrome.

Naheed B, Kuiper JH, Uthman OA, O'Mahony F, O'Brien PM.

Cochrane Database Syst Rev. 2017 Mar 3;3:CD010503. doi: 10.1002/14651858.CD010503.pub2. Review.

2.

Fourth consensus of the International Society for Premenstrual Disorders (ISPMD): auditable standards for diagnosis and management of premenstrual disorder.

Ismaili E, Walsh S, O'Brien PMS, Bäckström T, Brown C, Dennerstein L, Eriksson E, Freeman EW, Ismail KMK, Panay N, Pearlstein T, Rapkin A, Steiner M, Studd J, Sundström-Paromma I, Endicott J, Epperson CN, Halbreich U, Reid R, Rubinow D, Schmidt P, Yonkers K; Consensus Group of the International Society for Premenstrual Disorders.

Arch Womens Ment Health. 2016 Dec;19(6):953-958. doi: 10.1007/s00737-016-0631-7. Epub 2016 Jul 5.

PMID:
27378473
3.

Selective serotonin reuptake inhibitors for premenstrual syndrome.

Marjoribanks J, Brown J, O'Brien PM, Wyatt K.

Cochrane Database Syst Rev. 2013 Jun 7;(6):CD001396. doi: 10.1002/14651858.CD001396.pub3. Review.

4.

ISPMD consensus on the management of premenstrual disorders.

Nevatte T, O'Brien PM, Bäckström T, Brown C, Dennerstein L, Endicott J, Epperson CN, Eriksson E, Freeman EW, Halbreich U, Ismail K, Panay N, Pearlstein T, Rapkin A, Reid R, Rubinow D, Schmidt P, Steiner M, Studd J, Sundström-Poromaa I, Yonkers K; Consensus Group of the International Society for Premenstrual Disorders.

Arch Womens Ment Health. 2013 Aug;16(4):279-91. doi: 10.1007/s00737-013-0346-y. Epub 2013 Apr 27.

5.

Potential strategies to avoid progestogen-induced premenstrual disorders.

Baker LJ, O'Brien PM.

Menopause Int. 2012 Jun;18(2):73-6. doi: 10.1258/mi.2012.012016. Review.

PMID:
22611226
6.

Premenstrual syndrome (PMS): a peri-menopausal perspective.

Baker LJ, O'Brien PM.

Maturitas. 2012 Jun;72(2):121-5. doi: 10.1016/j.maturitas.2012.03.007. Epub 2012 Apr 24. Review.

PMID:
22534048
7.

TLE3 expression is associated with sensitivity to taxane treatment in ovarian carcinoma.

Samimi G, Ring BZ, Ross DT, Seitz RS, Sutherland RL, O'Brien PM, Hacker NF, Huh WK.

Cancer Epidemiol Biomarkers Prev. 2012 Feb;21(2):273-9. doi: 10.1158/1055-9965.EPI-11-0917. Epub 2011 Dec 22.

8.

Integrative genome-wide expression and promoter DNA methylation profiling identifies a potential novel panel of ovarian cancer epigenetic biomarkers.

Gloss BS, Patterson KI, Barton CA, Gonzalez M, Scurry JP, Hacker NF, Sutherland RL, O'Brien PM, Clark SJ.

Cancer Lett. 2012 May 1;318(1):76-85. doi: 10.1016/j.canlet.2011.12.003. Epub 2011 Dec 9.

PMID:
22155104
9.

Prognostic and diagnostic significance of DNA methylation patterns in high grade serous ovarian cancer.

Montavon C, Gloss BS, Warton K, Barton CA, Statham AL, Scurry JP, Tabor B, Nguyen TV, Qu W, Samimi G, Hacker NF, Sutherland RL, Clark SJ, O'Brien PM.

Gynecol Oncol. 2012 Mar;124(3):582-8. doi: 10.1016/j.ygyno.2011.11.026. Epub 2011 Nov 22.

PMID:
22115852
10.

Towards a consensus on diagnostic criteria, measurement and trial design of the premenstrual disorders: the ISPMD Montreal consensus.

O'Brien PM, Bäckström T, Brown C, Dennerstein L, Endicott J, Epperson CN, Eriksson E, Freeman E, Halbreich U, Ismail KM, Panay N, Pearlstein T, Rapkin A, Reid R, Schmidt P, Steiner M, Studd J, Yonkers K.

Arch Womens Ment Health. 2011 Feb;14(1):13-21. doi: 10.1007/s00737-010-0201-3. Epub 2011 Jan 12. Review.

11.

Monoclonal antibody targeting MUC1 and increasing sensitivity to docetaxel as a novel strategy in treating human epithelial ovarian cancer.

Wang L, Chen H, Liu F, Madigan MC, Power CA, Hao J, Patterson KI, Pourgholami MH, O'Brien PM, Perkins AC, Li Y.

Cancer Lett. 2011 Jan 28;300(2):122-33. doi: 10.1016/j.canlet.2010.09.013. Epub 2010 Nov 13.

PMID:
21075513
12.

MAL2 and tumor protein D52 (TPD52) are frequently overexpressed in ovarian carcinoma, but differentially associated with histological subtype and patient outcome.

Byrne JA, Maleki S, Hardy JR, Gloss BS, Murali R, Scurry JP, Fanayan S, Emmanuel C, Hacker NF, Sutherland RL, Defazio A, O'Brien PM.

BMC Cancer. 2010 Sep 17;10:497. doi: 10.1186/1471-2407-10-497.

13.

DUSP26 negatively affects the proliferation of epithelial cells, an effect not mediated by dephosphorylation of MAPKs.

Patterson KI, Brummer T, Daly RJ, O'Brien PM.

Biochim Biophys Acta. 2010 Sep;1803(9):1003-12. doi: 10.1016/j.bbamcr.2010.03.014. Epub 2010 Mar 27.

14.

Discovery of (pyridin-4-yl)-2H-tetrazole as a novel scaffold to identify highly selective matrix metalloproteinase-13 inhibitors for the treatment of osteoarthritis.

Schnute ME, O'Brien PM, Nahra J, Morris M, Howard Roark W, Hanau CE, Ruminski PG, Scholten JA, Fletcher TR, Hamper BC, Carroll JN, Patt WC, Shieh HS, Collins B, Pavlovsky AG, Palmquist KE, Aston KW, Hitchcock J, Rogers MD, McDonald J, Johnson AR, Munie GE, Wittwer AJ, Man CF, Settle SL, Nemirovskiy O, Vickery LE, Agawal A, Dyer RD, Sunyer T.

Bioorg Med Chem Lett. 2010 Jan 15;20(2):576-80. doi: 10.1016/j.bmcl.2009.11.081. Epub 2009 Nov 22.

PMID:
20005097
15.

Collagen and calcium-binding EGF domains 1 is frequently inactivated in ovarian cancer by aberrant promoter hypermethylation and modulates cell migration and survival.

Barton CA, Gloss BS, Qu W, Statham AL, Hacker NF, Sutherland RL, Clark SJ, O'Brien PM.

Br J Cancer. 2010 Jan 5;102(1):87-96. doi: 10.1038/sj.bjc.6605429. Epub 2009 Nov 24.

16.

Expression of urokinase plasminogen activator and its receptor in advanced epithelial ovarian cancer patients.

Wang L, Madigan MC, Chen H, Liu F, Patterson KI, Beretov J, O'Brien PM, Li Y.

Gynecol Oncol. 2009 Aug;114(2):265-72. doi: 10.1016/j.ygyno.2009.04.031. Epub 2009 May 17.

PMID:
19450871
17.

Dual-specificity phosphatases: critical regulators with diverse cellular targets.

Patterson KI, Brummer T, O'Brien PM, Daly RJ.

Biochem J. 2009 Mar 15;418(3):475-89. Review.

PMID:
19228121
18.

Systematic review of the effects of aromatase inhibitors on pain associated with endometriosis.

El-Gizawy Z, Tzakas E, O'Brien PM.

BJOG. 2008 Dec;115(13):1721-2; author reply 1722. doi: 10.1111/j.1471-0528.2008.01972.x. No abstract available.

19.

Epigenetic markers of ovarian cancer.

Barton CA, Clark SJ, Hacker NF, O'Brien PM.

Adv Exp Med Biol. 2008;622:35-51. doi: 10.1007/978-0-387-68969-2_4. Review. No abstract available.

PMID:
18546617
20.

Premenstrual syndrome.

Yonkers KA, O'Brien PM, Eriksson E.

Lancet. 2008 Apr 5;371(9619):1200-10. doi: 10.1016/S0140-6736(08)60527-9.

21.

The E3 ubiquitin ligase EDD is an adverse prognostic factor for serous epithelial ovarian cancer and modulates cisplatin resistance in vitro.

O'Brien PM, Davies MJ, Scurry JP, Smith AN, Barton CA, Henderson MJ, Saunders DN, Gloss BS, Patterson KI, Clancy JL, Heinzelmann-Schwarz VA, Murali R, Scolyer RA, Zeng Y, Williams ED, Scurr L, Defazio A, Quinn DI, Watts CK, Hacker NF, Henshall SM, Sutherland RL.

Br J Cancer. 2008 Mar 25;98(6):1085-93. doi: 10.1038/sj.bjc.6604281. Epub 2008 Mar 18. Erratum in: Br J Cancer. 2008 Jun 3;98(11):1880. Murali, Rajmohan [added].

22.

DNA methylation changes in ovarian cancer: implications for early diagnosis, prognosis and treatment.

Barton CA, Hacker NF, Clark SJ, O'Brien PM.

Gynecol Oncol. 2008 Apr;109(1):129-39. doi: 10.1016/j.ygyno.2007.12.017. Epub 2008 Jan 29. Review.

PMID:
18234305
23.

Serotonin receptor 1A C(-1019)G polymorphism associated with premenstrual dysphoric disorder.

Dhingra V, Magnay JL, O'Brien PM, Chapman G, Fryer AA, Ismail KM.

Obstet Gynecol. 2007 Oct;110(4):788-92.

PMID:
17906010
24.

Low meprin alpha expression differentiates primary ovarian mucinous carcinoma from gastrointestinal cancers that commonly metastasise to the ovaries.

Heinzelmann-Schwarz VA, Scolyer RA, Scurry JP, Smith AN, Gardiner-Garden M, Biankin AV, Baron-Hay S, Scott C, Ward RL, Fink D, Hacker NF, Sutherland RL, O'Brien PM.

J Clin Pathol. 2007 Jun;60(6):622-6. Epub 2006 Jul 5.

25.

Are there differential symptom profiles that improve in response to different pharmacological treatments of premenstrual syndrome/premenstrual dysphoric disorder?

Halbreich U, O'Brien PM, Eriksson E, Bäckström T, Yonkers KA, Freeman EW.

CNS Drugs. 2006;20(7):523-47. Review.

PMID:
16800714
26.

Repair techniques for obstetric anal sphincter injuries: a randomized controlled trial.

Fernando RJ, Sultan AH, Kettle C, Radley S, Jones P, O'Brien PM.

Obstet Gynecol. 2006 Jun;107(6):1261-8.

PMID:
16738150
27.

A distinct molecular profile associated with mucinous epithelial ovarian cancer.

Heinzelmann-Schwarz VA, Gardiner-Garden M, Henshall SM, Scurry JP, Scolyer RA, Smith AN, Bali A, Vanden Bergh P, Baron-Hay S, Scott C, Fink D, Hacker NF, Sutherland RL, O'Brien PM.

Br J Cancer. 2006 Mar 27;94(6):904-13.

28.
29.

The effect of prostanoid precursors and inhibitors on platelet angiotensin II binding.

Walker T, Singh PK, Wyatt KM, O'Brien PM.

J Obstet Gynaecol. 1999 Jan;19(1):56-8.

PMID:
15512224
30.

E5 protein of human papillomavirus type 16 selectively downregulates surface HLA class I.

Ashrafi GH, Haghshenas MR, Marchetti B, O'Brien PM, Campo MS.

Int J Cancer. 2005 Jan 10;113(2):276-83.

31.

Cyclin D1, p53, and p21Waf1/Cip1 expression is predictive of poor clinical outcome in serous epithelial ovarian cancer.

Bali A, O'Brien PM, Edwards LS, Sutherland RL, Hacker NF, Henshall SM.

Clin Cancer Res. 2004 Aug 1;10(15):5168-77.

32.

Overexpression of the cell adhesion molecules DDR1, Claudin 3, and Ep-CAM in metaplastic ovarian epithelium and ovarian cancer.

Heinzelmann-Schwarz VA, Gardiner-Garden M, Henshall SM, Scurry J, Scolyer RA, Davies MJ, Heinzelmann M, Kalish LH, Bali A, Kench JG, Edwards LS, Vanden Bergh PM, Hacker NF, Sutherland RL, O'Brien PM.

Clin Cancer Res. 2004 Jul 1;10(13):4427-36.

33.

The effectiveness of GnRHa with and without 'add-back' therapy in treating premenstrual syndrome: a meta analysis.

Wyatt KM, Dimmock PW, Ismail KM, Jones PW, O'Brien PM.

BJOG. 2004 Jun;111(6):585-93. Review.

34.

Sequence variants of bovine papillomavirus E5 detected in equine sarcoids.

Chambers G, Ellsmore VA, O'Brien PM, Reid SW, Love S, Campo MS, Nasir L.

Virus Res. 2003 Oct;96(1-2):141-5.

PMID:
12951274
35.

Papillomaviruses: a correlation between immune evasion and oncogenicity?

O'Brien PM, Campo MS.

Trends Microbiol. 2003 Jul;11(7):300-5. No abstract available.

PMID:
12875812
36.

Association of bovine papillomavirus with the equine sarcoid.

Chambers G, Ellsmore VA, O'Brien PM, Reid SWJ, Love S, Campo MS, Nasir L.

J Gen Virol. 2003 May;84(Pt 5):1055-1062. doi: 10.1099/vir.0.18947-0. Review.

PMID:
12692268
37.

No association of sleep with total daily physical activity in normal sleepers.

Youngstedt SD, Perlis ML, O'Brien PM, Palmer CR, Smith MT, Orff HJ, Kripke DF.

Physiol Behav. 2003 Mar;78(3):395-401.

PMID:
12676274
39.

Selective serotonin reuptake inhibitors for premenstrual syndrome.

Wyatt KM, Dimmock PW, O'Brien PM.

Cochrane Database Syst Rev. 2002;(4):CD001396. Review. Update in: Cochrane Database Syst Rev. 2009;(2):CD001396.

PMID:
12519554
40.
41.

Evasion of host immunity directed by papillomavirus-encoded proteins.

O'Brien PM, Saveria Campo M.

Virus Res. 2002 Sep;88(1-2):103-17. Review.

PMID:
12297330
42.

Menstrual symptometrics: a simple computer-aided method to quantify menstrual cycle disorders.

Wyatt KM, Dimmock PW, Hayes-Gill B, Crowe J, O'Brien PM.

Fertil Steril. 2002 Jul;78(1):96-101.

PMID:
12095497
43.
44.

Bacterial expression and purification of recombinant bovine Fab fragments.

O'Brien PM, Maxwell G, Campo MS.

Protein Expr Purif. 2002 Feb;24(1):43-50.

PMID:
11812221
45.

Down-regulation of MHC class I by bovine papillomavirus E5 oncoproteins.

Ashrafi GH, Tsirimonaki E, Marchetti B, O'Brien PM, Sibbet GJ, Andrew L, Campo MS.

Oncogene. 2002 Jan 10;21(2):248-59.

46.

Immunoglobulin genes expressed by B-lymphocytes infiltrating cervical carcinomas show evidence of antigen-driven selection.

O'Brien PM, Tsirimonaki E, Coomber DW, Millan DW, Davis JA, Campo MS.

Cancer Immunol Immunother. 2001 Dec;50(10):523-32.

PMID:
11776374
47.

Emergency medicine and public health: new steps in old directions.

Pollock DA, Lowery DW, O'brien PM.

Ann Emerg Med. 2001 Dec;38(6):675-83.

PMID:
11719749
48.

Determination of total menstrual blood loss.

Wyatt KM, Dimmock PW, Walker TJ, O'Brien PM.

Fertil Steril. 2001 Jul;76(1):125-31.

PMID:
11438330
49.

Matrix metalloproteinase inhibition attenuates left ventricular remodeling and dysfunction in a rat model of progressive heart failure.

Peterson JT, Hallak H, Johnson L, Li H, O'Brien PM, Sliskovic DR, Bocan TM, Coker ML, Etoh T, Spinale FG.

Circulation. 2001 May 8;103(18):2303-9.

PMID:
11342481
50.

Stereoselective binding of an enantiomeric pair of stromelysin-1 inhibitors caused by conformational entropy factors.

Parker MH, Ortwine DF, O'Brien PM, Lunney EA, Banotai CA, Mueller WT, McConnell P, Brouillette CG.

Bioorg Med Chem Lett. 2000 Nov 6;10(21):2427-30.

PMID:
11078193

Supplemental Content

Loading ...
Support Center